Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Dec
06
UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting
Nov
26
UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting
Nov
20
UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa
Nov
14
New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis
Oct
15
UCB announces U.S. launch of UCB Myasthenia Gravis Scholarship™ for people impacted by myasthenia gravis in the U.S.
Oct
14
UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (bimekizumab-bkzx)
Oct
11
UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
Sep
30
UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis
Sep
25
UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
